Here, we show that WIP1 constitutes a druggable target in neuroblastoma and medulloblastoma that should be further developed and evaluated in combination with current treatment modalities and investigated for testing in clinical trials, given the fact that the majority of patients with poor prognosis have aberrant expression of WIP1 [34,82]. The gene discussed is PPM1D; the disease is neuroblastoma.